全球抗凝血逆轉藥物市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢與預測

全球抗凝血逆轉藥物市場需求預計將從 2023 年的 123128 萬美元達到 2032 年近 427086 萬美元的市場規模，2024-2032 年研究期間複合年成長率為 14.82%。

抗凝血逆轉藥物是用於抵消抗凝血藥物影響的藥物，例如直介面服抗凝血劑 (DOAC) 和華法林，特別是在出血緊急情況或需要快速逆轉抗凝血藥物時（例如手術前）。這些藥物透過促進血栓形成或抑制抗凝血劑的活性來幫助止血。常用的抗凝血逆轉劑包括維生素 K、凝血酶原複合物濃縮物 (PCC) 和 DOAC 的特異性逆轉劑，例如用於達比加群的 idarucizumab 和用於 Xa 因子抑制劑的 andexanet alfa。

市場動態

心血管疾病盛行率的增加、外科手術數量的增加以及抗凝血治療的進步等因素推動了抗凝血逆轉藥物市場的發展。心血管疾病通常需要抗凝血治療來預防血栓，但這些治療可能會導致併發症，需要使用抗凝血逆轉藥物。老年人口的增加，更容易罹患心血管疾病，也增加了這些藥物的需求。此外，擇期手術和急診手術數量的不斷增加，需要有效的抗凝血逆轉劑來控制手術期間和手術後的出血風險。抗凝血藥物的創新促進了新型逆轉劑的開發，改善了患者的治療效果並推動了市場成長。已開發和發展中地區的監管批准和醫療保健支出的增加進一步支持了市場擴張。然而，安全問題和臨床應用有限可能會阻礙未來幾年抗凝血逆轉藥物市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球抗凝血逆轉藥物市場的各個細分市場進行了包容性評估。抗凝血逆轉藥物產業的成長和趨勢為本研究提供了整體方法。

市場區隔

抗凝血逆轉藥物市場報告的這一部分提供了國家和區域層面細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人群以及即將到來的機會。

依產品類型

• 凝血酶原複合物濃縮物
• 植物萘二酮
• 安德薩內特阿爾法
• 伊達賽珠單抗
• 魚精蛋白
• 其他

按配銷通路

• 醫院藥房
• 零售藥房
• 網路藥房

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲抗凝血逆轉藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。抗凝血逆轉藥物市場的主要參與者包括Portola Pharmaceuticals、勃林格殷格翰、CSL Behring、Bausch Health Companies Inc.、Octapharma AG、Dr. Reddy'S Laboratories、AMAG Pharmaceuticals Inc.、輝瑞公司、SGPharma Pvt.有限公司、阿爾卑斯製藥工業股份有限公司、費森尤斯卡比股份公司。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

目錄

第1章：前言

• 報告說明
  • 客觀的
  • 目標受眾
  • 獨特的銷售主張 (USP) 和產品
• 研究範圍
• 研究方法
  • 市場研究過程
  • 市場研究方法論

第 2 章：執行摘要

• 市場亮點
• 全球市場概況

第 3 章：抗凝血逆轉藥物 - 產業分析

• 簡介 - 市場動態
• 市場促進因素
• 市場限制
• 機會
• 產業動態
• 波特五力分析
• 市場吸引力分析
  • 市場吸引力分析：按產品類型
  • 按配銷通路分類的市場吸引力分析
  • 市場吸引力分析：按地區

第 4 章：價值鏈分析

• 價值鏈分析
• 原料分析
  • 原料清單
  • 原料廠商清單
  • 主要原物料價格走勢
• 潛在買家名單
• 行銷管道
  • 直效行銷
  • 間接行銷
  • 行銷通路發展趨勢

第 5 章：全球抗凝血逆轉藥物市場分析：依產品類型

• 概述：按產品類型
• 歷史與預測資料分析：按產品類型
• 凝血酶原複合物濃縮物
• 植物萘二酮
• 安德薩內特阿爾法
• 伊達賽珠單抗
• 魚精蛋白
• 其他

第 6 章：全球抗凝血逆轉藥物市場分析：按分銷管道

• 配銷通路概述
• 按配銷通路進行歷史和預測資料分析
• 醫院藥房
• 零售藥房
• 網路藥房

第 7 章：全球抗凝血逆轉藥物市場分析：依地理位置

• 區域展望
• 介紹
• 北美銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 北美按細分市場銷售分析
  • 北美按國家銷售分析
  • 美國銷售分析
  • 加拿大銷售分析
  • 墨西哥銷售分析
• 歐洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 歐洲按細分市場銷售分析
  • 歐洲按國家銷售分析
  • 英國銷售分析
  • 法國銷售分析
  • 德國銷售分析
  • 義大利銷售分析
  • 俄羅斯銷售分析
  • 歐洲其他地區銷售分析
• 亞太地區銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 亞太地區按細分市場銷售分析
  • 亞太地區按國家銷售分析
  • 中國銷售分析
  • 印度銷售分析
  • 日本銷售分析
  • 韓國銷售分析
  • 澳洲銷售分析
  • 東南亞銷售分析
  • 亞太地區其他地區銷售分析
• 拉丁美洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 拉丁美洲按細分市場銷售分析
  • 拉丁美洲按國家銷售分析
  • 巴西銷售分析
  • 阿根廷銷售分析
  • 秘魯銷售分析
  • 智利銷售分析
  • 拉丁美洲其他地區銷售分析
• 中東和非洲銷售分析
  • 概覽、歷史與預測資料銷售分析
  • 中東和非洲按細分市場銷售分析
  • 中東和非洲按國家銷售分析
  • 沙烏地阿拉伯銷售分析
  • 阿拉伯聯合大公國銷售分析
  • 以色列銷售分析
  • 南非銷售分析
  • 中東其他地區和非洲銷售分析

第 8 章：抗凝血逆轉藥物公司的競爭格局

• 抗凝血逆轉藥物市場競爭
• 夥伴關係/協作/協議
• 併購
• 新產品發布
• 其他發展

第 9 章：公司簡介

• 頂級公司市佔率分析
• 市場集中度
• Portola Pharmaceuticals
• 公司概況
• 公司收入
• 產品
• 最新動態
• Boehringer Ingelheim
• 公司概況
• 公司收入
• 產品
• 最新動態
• CSL Behring
• 公司概況
• 公司收入
• 產品
• 最新動態
• Bausch Health Companies Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Octapharma AG
• 公司概況
• 公司收入
• 產品
• 最新動態
• Dr. Reddy'S Laboratories
• 公司概況
• 公司收入
• 產品
• 最新動態
• AMAG Pharmaceuticals Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Pfizer Inc.
• 公司概況
• 公司收入
• 產品
• 最新動態
• SGPharma Pvt. Ltd.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Alps Pharmaceutical Ind. Co. Ltd.
• 公司概況
• 公司收入
• 產品
• 最新動態
• Fresenius Kabi AG
• 公司概況
• 公司收入
• 產品
• 最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

The global demand for Anticoagulant Reversal Drugs Market is presumed to reach the market size of nearly USD 4270.86 Million by 2032 from USD 1231.28 Million in 2023 with a CAGR of 14.82% under the study period 2024-2032.

Anticoagulant reversal drugs are medications used to counteract the impact of anticoagulant medications, such as direct oral anticoagulants (DOACs) and warfarin, particularly in bleeding emergencies or when rapid reversal of anticoagulation is necessary, such as before surgery. These drugs work by promoting clot formation or inhibiting the activity of anticoagulants to help stop bleeding. Commonly used anticoagulant reversal agents include vitamin K, prothrombin complex concentrates (PCCs), and specific reversal agents for DOACs, such as idarucizumab for dabigatran and andexanet alfa for factor Xa inhibitors.

MARKET DYNAMICS

Factors including the increasing prevalence of cardiovascular diseases, the growing number of surgical procedures, and advancements in anticoagulant therapies drive the anticoagulant reversal drugs market. Cardiovascular diseases often require anticoagulant treatments to prevent blood clots, but these treatments can lead to complications requiring the use of anticoagulant reversal drugs. The increasing elderly population, who are more susceptible to cardiovascular conditions, also contributes to the demand for these drugs. Additionally, the rising number of surgeries, both elective and emergency, necessitates the availability of effective anticoagulant reversal agents to manage bleeding risks during and after procedures. Innovations in anticoagulant drugs have led to the development of new reversal agents, improving patient outcomes and driving market growth. Regulatory approvals and increasing healthcare expenditures in developed and developing regions further support the market expansion. However, safety concerns and limited adoption in clinical settings may hinder the growth of the anticoagulant reversal drugs market in the next few years.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Anticoagulant Reversal Drugs. The growth and trends of Anticoagulant Reversal Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Anticoagulant Reversal Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Prothrombin Complex Concentrates
• Phytonadione
• Andexanet Alfa
• Idarucizumab
• Protamine
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Anticoagulant Reversal Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anticoagulant Reversal Drugs market include Portola Pharmaceuticals, Boehringer Ingelheim, CSL Behring, Bausch Health Companies Inc., Octapharma AG, Dr. Reddy'S Laboratories, AMAG Pharmaceuticals Inc., Pfizer Inc., SGPharma Pvt. Ltd., Alps Pharmaceutical Ind. Co. Ltd., Fresenius Kabi AG. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ANTICOAGULANT REVERSAL DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data Analysis By Product Type
• 5.3. Prothrombin Complex Concentrates Historic and Forecast Sales By Regions
• 5.4. Phytonadione Historic and Forecast Sales By Regions
• 5.5. Andexanet Alfa Historic and Forecast Sales By Regions
• 5.6. Idarucizumab Historic and Forecast Sales By Regions
• 5.7. Protamine Historic and Forecast Sales By Regions
• 5.8. Others Historic and Forecast Sales By Regions

6. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1. Overview By Distribution Channel
• 6.2. Historical and Forecast Data Analysis By Distribution Channel
• 6.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 6.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 6.5. Online Pharmacy Historic and Forecast Sales By Regions

7. GLOBAL ANTICOAGULANT REVERSAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2 North America By Segment Sales Analysis
  • 7.3.3 North America By Country Sales Analysis
  • 7.3.4 United States Sales Analysis
  • 7.3.5 Canada Sales Analysis
  • 7.3.6 Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2 Europe By Segment Sales Analysis
  • 7.4.3 Europe By Country Sales Analysis
  • 7.4.4 United Kingdom Sales Analysis
  • 7.4.5 France Sales Analysis
  • 7.4.6 Germany Sales Analysis
  • 7.4.7 Italy Sales Analysis
  • 7.4.8 Russia Sales Analysis
  • 7.4.9 Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2 Asia Pacific By Segment Sales Analysis
  • 7.5.3 Asia Pacific By Country Sales Analysis
  • 7.5.4 China Sales Analysis
  • 7.5.5 India Sales Analysis
  • 7.5.6 Japan Sales Analysis
  • 7.5.7 South Korea Sales Analysis
  • 7.5.8 Australia Sales Analysis
  • 7.5.9 South East Asia Sales Analysis
  • 7.5.10 Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2 Latin America By Segment Sales Analysis
  • 7.6.3 Latin America By Country Sales Analysis
  • 7.6.4 Brazil Sales Analysis
  • 7.6.5 Argentina Sales Analysis
  • 7.6.6 Peru Sales Analysis
  • 7.6.7 Chile Sales Analysis
  • 7.6.8 Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2 Middle East & Africa By Segment Sales Analysis
  • 7.7.3 Middle East & Africa By Country Sales Analysis
  • 7.7.4 Saudi Arabia Sales Analysis
  • 7.7.5 UAE Sales Analysis
  • 7.7.6 Israel Sales Analysis
  • 7.7.7 South Africa Sales Analysis
  • 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE ANTICOAGULANT REVERSAL DRUGS COMPANIES

• 8.1. Anticoagulant Reversal Drugs Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9. COMPANY PROFILES OF ANTICOAGULANT REVERSAL DRUGS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Portola Pharmaceuticals
  • 9.3.1 Company Overview
  • 9.3.2 Company Revenue
  • 9.3.3 Products
  • 9.3.4 Recent Developments
• 9.4. Boehringer Ingelheim
  • 9.4.1 Company Overview
  • 9.4.2 Company Revenue
  • 9.4.3 Products
  • 9.4.4 Recent Developments
• 9.5. CSL Behring
  • 9.5.1 Company Overview
  • 9.5.2 Company Revenue
  • 9.5.3 Products
  • 9.5.4 Recent Developments
• 9.6. Bausch Health Companies Inc.
  • 9.6.1 Company Overview
  • 9.6.2 Company Revenue
  • 9.6.3 Products
  • 9.6.4 Recent Developments
• 9.7. Octapharma AG
  • 9.7.1 Company Overview
  • 9.7.2 Company Revenue
  • 9.7.3 Products
  • 9.7.4 Recent Developments
• 9.8. Dr. Reddy'S Laboratories
  • 9.8.1 Company Overview
  • 9.8.2 Company Revenue
  • 9.8.3 Products
  • 9.8.4 Recent Developments
• 9.9. AMAG Pharmaceuticals Inc.
  • 9.9.1 Company Overview
  • 9.9.2 Company Revenue
  • 9.9.3 Products
  • 9.9.4 Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1 Company Overview
  • 9.10.2 Company Revenue
  • 9.10.3 Products
  • 9.10.4 Recent Developments
• 9.11. SGPharma Pvt. Ltd.
  • 9.11.1 Company Overview
  • 9.11.2 Company Revenue
  • 9.11.3 Products
  • 9.11.4 Recent Developments
• 9.12. Alps Pharmaceutical Ind. Co. Ltd.
  • 9.12.1 Company Overview
  • 9.12.2 Company Revenue
  • 9.12.3 Products
  • 9.12.4 Recent Developments
• 9.13. Fresenius Kabi AG
  • 9.13.1 Company Overview
  • 9.13.2 Company Revenue
  • 9.13.3 Products
  • 9.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers: Impact Analysis
• Restraints: Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• Analysis By Product Type (USD MN)
• Prothrombin Complex Concentrates Market Sales By Geography (USD MN)
• Phytonadione Market Sales By Geography (USD MN)
• Andexanet Alfa Market Sales By Geography (USD MN)
• Idarucizumab Market Sales By Geography (USD MN)
• Protamine Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Analysis By Distribution Channel (USD MN)
• Hospital Pharmacy Market Sales By Geography (USD MN)
• Retail Pharmacy Market Sales By Geography (USD MN)
• Online Pharmacy Market Sales By Geography (USD MN)
• Global Anticoagulant Reversal Drugs Market Sales By Geography (USD MN)
• North America Market Analysis (USD MN)
• United States Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate By Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Anticoagulant Reversal Drugs Report
• Market Research Process
• Market Research Methodology
• Global Anticoagulant Reversal Drugs Market Size, By Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis By Product Type
• Market Attractiveness Analysis By Distribution Channel
• Market Attractiveness Analysis By Region
• Value Chain Analysis
• Global Market Analysis By Product Type (USD MN)
• Prothrombin Complex Concentrates Market Sales By Geography (USD MN)
• Phytonadione Market Sales By Geography (USD MN)
• Andexanet Alfa Market Sales By Geography (USD MN)
• Idarucizumab Market Sales By Geography (USD MN)
• Protamine Market Sales By Geography (USD MN)
• Others Market Sales By Geography (USD MN)
• Global Market Analysis By Distribution Channel (USD MN)
• Hospital Pharmacy Market Sales By Geography (USD MN)
• Retail Pharmacy Market Sales By Geography (USD MN)
• Online Pharmacy Market Sales By Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.